A 52-year-old woman with known moderately severe tobacco-induced chronic obstructive pulmonary disease presents with fever and 2 days of left lower quadrant abdominal pain, fever, and an elevated white blood cell (WBC) count, with a predominance of polymorphonuclear leukocytes. During physical examination, the patient's temperature is 39ЊC, her blood pressure is 80/60 mm Hg, her pulse is 100 beats/min, and her respiratory rate is 18 breaths/min, with an oxygen saturation of 92% while breathing nasal oxygen at 2 L/ min. The abdomen is diffusely tender. There is rebound tenderness in the left lower quadrant. No bowel sounds are audible. Fluid resuscitation, empirical piperacillintazobactam, and vasopressors are initiated. Abdominal CT findings are consistent with a diagnosis of a ruptured peridiverticular abscess.
blood samples collected at admission are reported as positive for pansusceptible Escherichia coli. Unfortunately, the patient fails several spontaneous breathing trials, and mechanical ventilation is continued. On day 7 of mechanical ventilation, the nurses report purulent endotracheal tube suction specimens concomitant with a temperature increase back to 38.5ЊC. The WBC count is 16,000 cells/mL, and a portable chest radiograph shows a new right lower lobe infiltrate superimposed on changes consistent with emphysema. With a fraction of inspired oxygen of 35% and positive end-expiratory pressure of 5, the partial pressure of oxygen in arterial blood is 91 mm Hg. The patient is considered to be a suitable candidate for bronchoscopic examination.
During bronchoscopic examination, purulence is found in the right lower lobe bronchus, and both a suctioned specimen for culture and sensitivity and a quantitative protected specimen brush culture are obtained. Pending culture results, piperacillin-tazobactam therapy is continued. There are at least 4 possible culture results and associated interpretations (Table 1) .
DISCUSSION
This patient scenario raises many questions pertinent to the design of clinical trials of new drugs for the treatment of ventilator-associated bacterial pneumonia.
(1) What is the intent-to-treat and modified or microbiologic intent-to-treat definition of ventilator-associated bacterial pneumonia? (2) Is it possible to stratify severity of illness with use of a validated scoring system? 
